ERBB2 and triple-negative breast carcinoma: Furthermore, individual response to neoadjuvant therapy provides prognostic information and assists treatment decisions after surgery in patients with human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer.